-
CSCO 2024 | Dr. Shukui Qin: 27 Years of Advancing Cancer Treatment, A New Chapter in Liver Cancer Therapy
From September 25 to 29, 2024, the 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held in Xiamen. Themed “Patient-Centered, Shared Future,” the conference attracted tens of thousands of oncology experts and pharmaceutical…
-
Dr. Shaoming Wang’s In-depth Analysis: Global Lifetime Risk and Prevention Strategies for Gastrointestinal Cancer | CACA Integrated Esophageal Cancer
During the 2024 CACA Integrated Esophageal Cancer Academic Conference, Dr. Shaoming Wang from the Cancer Hospital Chinese Academy of Medical Sciences gave an in-depth explanation of research progress on the burden of upper gastrointestinal cancer. During the conference, Oncology Frontier had the pleasure of interviewing Professor Wang to further explore his team’s latest research findings…
-
CSCO 2024 | Dr. Zefei Jiang: Twenty Years of Mutual Achievement, From China to the World; A Preview of the Exciting 2024 CSCO Conference
From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, will be held in Xiamen. With the theme “Patient-Centered, Sharing the Future,” the conference will showcase important research advancements and…
-
Consensus from SIDP: Primary Prevention and Therapeutic Drug Monitoring (TDM) for Triazole Antifungal Drugs
Introduction: The Society of Infectious Disease Pharmacists (SIDP) presents its consensus recommendations for primary prevention and therapeutic drug monitoring (TDM) of five commonly used triazole antifungal drugs: voriconazole, posaconazole, itraconazole,…
-
ASTRO 2024 Highlights: Dr. Kristin Higgins on Optimal Sequence for SCLC Therapies
At the 2024 Annual Meeting of the American Society for Radiation Oncology (ASTRO), the second interim analysis of the Phase III NRG-LU005 trial revealed the importance of timing when combining immunotherapy with chemoradiotherapy for limited-stage small cell lung cancer (SCLC). The findings showed no significant survival benefits for patients who received atezolizumab concurrently with chemoradiotherapy…
-
CSCO 2024 | Dr. Ruihua Xu: Patient-Centered Approach to Innovating the Future of Cancer Treatment
From September 25 to 29, 2024, the 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, were held in Xiamen. The theme of this year’s conference was “Patient-Centered, Sharing the Future,” bringing together key research advancements and…
-
CUA 2024 Presents: Advancing Kidney-Sparing Strategies for UTUC
Radical nephroureterectomy (RNU) remains the gold standard treatment for upper tract urothelial carcinoma (UTUC). However, some patients with a solitary kidney or insufficient renal reserve may require alternative approaches to preserve kidney function. In recent years, advancements in systemic drug therapy and various endoscopic focal treatment techniques have provided kidney-sparing options for such patients. Nonetheless,…
-
ESMO 2024 Pioneers: Dr. Filippo Pietrantonio on the Cutting Edge of Upper GI Cancer Research
As one of the world’s largest and most academically prestigious clinical oncology conferences, the 2024 European Society for Medical Oncology (ESMO) conference, held from September 13 to 17 in Barcelona, drew global attention. The conference revealed several important clinical study results in upper gastrointestinal tumors. Dr. Filippo Pietrantonio, an oncologist from the National Cancer Institute…
Connecting Medical Expertise through Media